FTO and acute myeloid leukemia: Moreover, increased T-cell cytotoxicity and reduced self-renewal abilities of AML cells were noted in the treated mice, suggesting that CS1 and CS2 are potent inhibitors of FTO and can be developed as potential therapeutics against LSC by increasing anti-leukaemia T-cell activity [82].